Home / Health / Cancer Vaccine Sparks 240% Stock Surge
Cancer Vaccine Sparks 240% Stock Surge
17 Nov
Summary
- Cancer vaccine showed a 41% reduction in death risk.
- Trial met primary endpoint for overall survival.
- FDA discussions planned for accelerated filing strategy.
SELLAS Life Sciences Group announced significant positive topline results from its pivotal Phase 3 REGAL trial for galinpepimut-S (GPS), a novel immunotherapeutic cancer vaccine. The trial focused on patients with acute myeloid leukemia (AML) who had achieved complete remission but were ineligible for stem cell transplantation.
The REGAL trial successfully met its primary endpoint, demonstrating a substantial 41% reduction in the risk of death for patients treated with GPS compared to the best available treatment. This translated to a median overall survival of 24.0 months for the GPS group, versus 14.7 months for the control group.
GPS was observed to be generally well-tolerated, exhibiting a safety profile consistent with previous clinical studies and revealing no new safety signals. The adverse events reported were predominantly mild to moderate, with local injection site reactions being the most common. SELLAS is preparing to engage with the U.S. Food and Drug Administration to explore an accelerated filing strategy for GPS.
The company aims to advance preparations for a Biologics License Application submission, targeting the first half of 2027. Further comprehensive evaluations of secondary endpoints are currently underway and will be presented at an upcoming medical conference before submission for publication.